Value
4.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Fwd P/E | 8.3 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 14.2x
- ▸PEG: 0.00
LQDA · Why this verdict
Why Liquidia (LQDA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business scores 7.6 out of 10 on quality — a wide economic moat, a Piotroski health score of 8 out of 9, return on equity of 28%, and a Rule-of-40 result the notes characterize as elite — representing one of the strongest fundamental profiles in the healthcare specialty segment. Quality breakdown | The Piotroski score remains at 7 or above and operating margins stay positive over the next four reported quarters, confirming quality durability. | →Stable |
| CounterFree cash flow converts at only about 43 cents per dollar of reported net income — flagged as a red flag — meaning reported profits materially overstate cash generation; if conversion does not improve, the high-quality characterization may be softer than headline metrics suggest. | ||
The current price of $71.80 sits above the established take-profit target of $71.25, leaving the near-term geometric setup unfavorable with a negative risk/reward ratio and no remaining upside headroom to the resistance level. Price targets | Price pulls back below $65, restoring at least 9% upside to the take-profit target and creating a viable entry setup from a risk/reward standpoint. | →Stable |
| CounterThe analyst consensus price target may differ from and exceed the near-term resistance target; if earnings continue improving and analyst targets are revised upward, a new take-profit level could restore geometric favorability without requiring a price pullback. | ||
The business carries two high-severity concentration risks — revenue concentrated in a single product and sole-source supply relationships — creating binary exposure that can impair the entire revenue base if either concentration point is disrupted. Risk breakdown | A second product achieves at least 20% of total revenue for 2 consecutive quarters, meaningfully reducing single-product concentration risk. | →Stable |
| CounterSingle-product focus in specialty pharma can reflect deliberate prioritization of a high-moat market position rather than fragility; a wide economic moat around the concentrated product may provide stronger protection than premature diversification into less-defensible areas. | ||
Momentum scores 7.5 out of 10 — with rising on-balance volume, the price above its 200-day moving average, and improving MACD — but RSI at 71 signals overbought conditions that can precede near-term consolidation or a pullback. Momentum breakdown | RSI retreats below 60 while price holds above the 200-day moving average for 2 consecutive months, resetting momentum to a healthier level without breaking the uptrend. | →Stable |
| CounterOverbought RSI readings in strongly trending stocks can persist for extended periods; the combination of rising on-balance volume and above-average-MA positioning suggests the uptrend may continue before a meaningful pullback occurs. | ||
Analyst earnings estimates have risen 5.4% over the past 30 days, a positive revision trend that reflects growing analyst confidence in the earnings trajectory and typically precedes continued price appreciation. Catalyst breakdown | Consensus EPS estimates continue rising at a pace of at least 3% per 30-day period for two consecutive months, confirming the upward revision cycle is sustained. | →Stable |
| CounterWith short interest at 14% of the float, a meaningful portion of market participants is betting against the current earnings trajectory; if the next quarter disappoints, the estimate revision trend can reverse sharply and the high short interest could amplify the downward price reaction. | ||
The business scores 7.6 out of 10 on quality — a wide economic moat, a Piotroski health score of 8 out of 9, return on equity of 28%, and a Rule-of-40 result the notes characterize as elite — representing one of the strongest fundamental profiles in the healthcare specialty segment.
→StableQuality breakdown
- Expectation
- The Piotroski score remains at 7 or above and operating margins stay positive over the next four reported quarters, confirming quality durability.
CounterFree cash flow converts at only about 43 cents per dollar of reported net income — flagged as a red flag — meaning reported profits materially overstate cash generation; if conversion does not improve, the high-quality characterization may be softer than headline metrics suggest.
The current price of $71.80 sits above the established take-profit target of $71.25, leaving the near-term geometric setup unfavorable with a negative risk/reward ratio and no remaining upside headroom to the resistance level.
→StablePrice targets
- Expectation
- Price pulls back below $65, restoring at least 9% upside to the take-profit target and creating a viable entry setup from a risk/reward standpoint.
CounterThe analyst consensus price target may differ from and exceed the near-term resistance target; if earnings continue improving and analyst targets are revised upward, a new take-profit level could restore geometric favorability without requiring a price pullback.
The business carries two high-severity concentration risks — revenue concentrated in a single product and sole-source supply relationships — creating binary exposure that can impair the entire revenue base if either concentration point is disrupted.
→StableRisk breakdown
- Expectation
- A second product achieves at least 20% of total revenue for 2 consecutive quarters, meaningfully reducing single-product concentration risk.
CounterSingle-product focus in specialty pharma can reflect deliberate prioritization of a high-moat market position rather than fragility; a wide economic moat around the concentrated product may provide stronger protection than premature diversification into less-defensible areas.
Momentum scores 7.5 out of 10 — with rising on-balance volume, the price above its 200-day moving average, and improving MACD — but RSI at 71 signals overbought conditions that can precede near-term consolidation or a pullback.
→StableMomentum breakdown
- Expectation
- RSI retreats below 60 while price holds above the 200-day moving average for 2 consecutive months, resetting momentum to a healthier level without breaking the uptrend.
CounterOverbought RSI readings in strongly trending stocks can persist for extended periods; the combination of rising on-balance volume and above-average-MA positioning suggests the uptrend may continue before a meaningful pullback occurs.
Analyst earnings estimates have risen 5.4% over the past 30 days, a positive revision trend that reflects growing analyst confidence in the earnings trajectory and typically precedes continued price appreciation.
→StableCatalyst breakdown
- Expectation
- Consensus EPS estimates continue rising at a pace of at least 3% per 30-day period for two consecutive months, confirming the upward revision cycle is sustained.
CounterWith short interest at 14% of the float, a meaningful portion of market participants is betting against the current earnings trajectory; if the next quarter disappoints, the estimate revision trend can reverse sharply and the high short interest could amplify the downward price reaction.
TrendMatrix Research · core thesis
Engine thesis — one sentence
An exceptionally high-quality franchise with a wide economic moat, elite-tier efficiency metrics, and strong upward price momentum now trades above its near-term take-profit target, leaving the risk/reward geometry unfavorable; the quality profile and rising analyst estimates are constructive over a longer horizon, but single-product concentration risk and high short interest make the current price unattractive for new entry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 9.4 |
| ROA | 6.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 3.9 |
| Current ratio | 7.7 |
| FCF quality | 3.4 |
| Moat | 7.5 |
| Rule of 40 | 9.5 |
| Piotroski F | 8.9 |
- ▸Excellent ROE: 28%
- ▸Earnings quality RED FLAG: 43% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
5.0/10data confidence 50%Momentum
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 8.5 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 7.9 |
| Price target | 4.1 |
- ▸Light analyst coverage (8.0) — signal dampened
Insider
3.1/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.1 |
| holder change | 5.1 |
- ▸Heavy insider selling — $143,382,639 (2.043% of mkt cap)
Peer rank
4.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.0 |
| quality rank | 7.2 |
| growth rank | 10.0 |
- ▸Superior ROE vs peers
- ▸Industry growth leader
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.9 |
| support resistance | 0.7 |
| 52w position | 9.6 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.4 |
| days to cover | 4.2 |
| volatility | 0.0 |
| put call | 5.9 |
| implied vol | 0.0 |
| beta | 9.7 |
| debt equity | 3.6 |
| news risk | 5.0 |
- ▸Short squeeze setup: 16% short, quality 7.5
- ▸High IV: 102%
- ▸Concentration risks: 2 HIGH, 2 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 8.5 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 7.1 |
| news activity | 8.0 |
- ▸Estimates up 5.4% (30d)
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:4.7>=4.5
- 8K:CLEAN
- NEWS_BOOST:ANALYST_CLUSTER(8)
- EARNINGS_PROXIMITY:40d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:-1.2=NEGATIVE
- INSIDER:2.04%=EXTREME
Warning (1)
- MOMENTUM:4.7<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
-1.21
Upside
-18.2%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 64, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.1 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Quality at 7.6) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-1.2=NEGATIVE, INSIDER:2.04%=EXTREME) reinforce the read. Current asymmetry R:R is -1.21 — supplementary context, not the trigger for this path.
The strongest dimensions are Quality at 7.6, Catalyst at 6.4, and Sentiment at 6.3; the weakest are Insider at 3.1, Technical at 4.1, and Peer rank at 4.3. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of -1.21 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Exceptional Franchise Quality
Trip ifPiotroski F-Score falls below 6 for 2 consecutive reporting periods, indicating material quality deterioration.
- P2Price Above Take Profit Level
Trip ifPrice falls below $65, restoring at least 9% upside to the $71.25 take-profit target and resetting the entry setup.
- P3Single Product Supplier Concentration
Trip ifA second product achieves at least 20% of total revenue for 2 consecutive quarters, reducing single-product concentration.
- P4Strong Overbought Momentum
Trip ifRSI stays above 65 for 2 consecutive months while price continues making new highs above $75, demonstrating the overbought signal is not predictive of consolidation.
- P5Rising Analyst Estimates
Trip ifConsensus EPS estimate falls by more than 10% over any 30-day window, reversing the upward revision trend.